Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF vs entecavir for prevention of HBV-related hepatocellular carcinoma recurrence after hepatectomy
ChiCTR2200063159Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in hepatocellular carcinoma (HCC) and Chronic Hepatitis B (CHB) comparing TAF group with ETV group (2 arms). Primary endpoint: Recurrence-free survival. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
tenofovir alafenamideentecavir
03
Conditions
hepatocellular carcinoma (HCC)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200063159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063159.